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Today angiotensin II inhibition is primarily used to slow the
rate of progression of kidney diseases. There is evidence that
these therapies can induce a partial regression of glomerular
lesions. However, we do not know yet the extent of sclerotic
lesion regression and whether new glomerular tissue is
formed to help support the renal function. We used male
Munich Wistar Fromter (MWF) rats, an experimental model for
progressive kidney disease, to quantify kidney structural
lesions upon angiotensin-converting enzyme (ACE) inhibition
therapy. Animals were studied at 50 weeks of age, when renal
function and structure are severely altered, and after a
10-week observation period, without or with treatment with
lisinopril (80 mg/l in drinking water). A group of untreated
Wistar rats was used as controls. With age, proteinuria, and
serum creatinine worsen, but lisinopril almost normalized
proteinuria and stabilized serum creatinine. Serial section
analysis of whole glomerular tufts showed that at baseline,
glomerulosclerosis affected the entire glomerular population,
and that these changes further increased with age.
Lisinopril significantly reduced incidence and extent of
glomerulosclerosis, with the presence of glomerular tufts not
affected by sclerosis (23% of glomeruli). Glomerular volume
was not significantly affected by treatment, and glomerular
mass spared from sclerosis increased from 46.9 to 65.5% upon
treatment, indicating consistent regeneration of glomerular
tissue. Lisinopril normalized baseline glomerular transforming
growth factor-beta and a-smooth muscle actin overexpression,
and prevented worsening of interstitial changes. Hence, ACE
inhibition, which is widely used in human kidney disease, may
not only halt the progression of renal failure, but also actually
induce the regeneration of new renal tissue.
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Five hundred million individuals, world wide,1 are estimated
to suffer some degree of chronic renal disease, and the
number may double in the next 10 years. Most of these
patients will succumb to cardiovascular events, while others
will develop end-stage renal disease (ESRD). This condition
will heavily affect medical care in the next years, with an
increase in costs, which will be difficult to support in the
industrialized countries, while the costs for such programs
are simply not applicable in low-income countries. Experi-
mental and human studies focused on the progressive nature
of kidney diseases have suggested a common pathogenetic
mechanism of kidney function loss, even when the initial
insult is removed.2–5 Currently available therapies help in
slowing the rate of progression of renal disease, and
effectively retard the need for dialysis.6 Whether such
treatments, based on angiotensin II (AII) antagonism (with
angiotensin-converting enzyme (ACE) inhibitors or AII
receptor blockade), besides preventing the evolution of renal
structural changes,7,8 are capable of regenerating renal tissue,
is difficult to establish in humans.
We have previously demonstrated that amelioration of
renal function and regression of structural changes can be
induced in susceptible Munich Wistar Fromter (MWF) rats,
which genetically develop proteinuria and glomerulosclerosis
with age, by the use of drugs that inhibit AII.9,10 Glomeruli
with early sclerotic lesions were remodeled in such a way that
sclerotic changes reduced in extensiveness. Others have
shown similar findings in models of progressive renal
diseases, such as puromycin aminonucleoside nephropathy,
aging and 5/6 nephrectomy.11–14 These studies are based on
the observation of single tissue sections, and we have shown
that single section evaluation of sclerotic changes under-
estimates the incidence and extent of sclerosis in experi-
mental and human studies when compared with the
complete three-dimensional (3D) reconstruction of the
capillary tuft.15,16 Here, we performed morphometrical
analysis of the glomerular capillary tuft, using digital
processing of serial section images, for 3D estimation of
individual capillary tuft volume and the volume occupied by
sclerosis. We investigated whether ACE inhibition therapy
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given to MWF rats at the late stage of kidney diseases, when
they already manifested heavy proteinuria and severe kidney
structural changes, still induces regression of glomerular
lesions. Specifically, we quantified to what extent regression
of advanced glomerular structural changes, if any, is truly
taking place and whether it is related to the regeneration of
normal tissue. We also evaluated whether regression of renal
structural injury was associated with changes in transforming
growth factor-beta (TGF-b) expression and in a-smooth
muscle actin (a-SMA) expression, respectively, a profibro-
genic cytokine TGF-b,17 and a marker of myofibroblast
differentiation.18 Age-matched Wistar rats were used as
normal controls to take into account aging effects.
RESULTS
As expected, male MWF rats developed massive proteinuria
and loss of kidney function during their life, as shown in
Figure 1. At the age of 50 weeks, urinary protein excretion
averaged 571762 mg/24 h (MWF 50W) and further in-
creased with age in the MWF 60W group (8077166 mg/
24 h). In animals given the ACE inhibitor (MWFþ LIS),
urinary protein excretion almost normalized in the 10-week
treatment period, averaging 120756 mg/24 h by the end of
the treatment (i.e. 60 weeks of age). Untreated MWF rats also
showed elevated serum creatinine (1.2270.15 and
1.9270.77 mg/dl, respectively, at 50 and 60 weeks of age,
Po0.01). This rise in serum creatinine was completely
prevented by the ACE inhibitor treatment. In this group of
rats, serum creatinine remained stable with time, being
comparable at 50 and 60 weeks of age.
In line with previous reports,19 at conventional light
microscopy, glomerular capillary tufts in MWF were
frequently affected by segmental or global sclerotic changes
already at 50 weeks of age, as reported in Table 1 and in
Figure 2. Glomerulosclerosis (GS) index averaged 3.4 (range
2.7–3.7) and 3.7 (range 3.6–4.0), respectively, in untreated
MWF rats at 50 and 60 weeks of age, values close to the upper
limit of this parameter. In animals treated with lisinopril, GS
index was significantly lower (2.9, range 1.7–3.4, Po0.05)
than that observed in untreated animals at the same age (60
weeks) and numerically lower than that estimated at 50 weeks
of age (see representative Figure 2). The normal Wistar rat at
60 weeks of age was also affected by sclerosis, but to a much
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Figure 1 | Urinary protein excretion and serum creatinine in
untreated and in lisinopril-treated MWF rats, and in control
Wistar rats, from 50 to 60 weeks of age. **Po0.01 vs Wistar rats at
same age, 1Po0.05 vs MWF rats at same age and 11Po0.01 vs MWF
rats at same age.
Table 1 | Structural changes of kidney tissue in MWF and in
Wistar rats
MWF 50W MWF 60W MWF+LIS Wistar
Age 50 weeks 60 weeks 60 weeks 60 weeks
GS Index 3.4 3.7 2.9* 1.111
(score) (2.7–3.7) (3.6–4.0) (1.7–3.4) (0.8–1.6)
Interstitial
Volume (%) 32.275.3 39.673.3# 31.074.5++ 9.970.311
Atrophic tubuli 2.5 2.5 2.0 0.811
(score) (2–3) (1–3) (1–2) (0–1)
Interstial inflammation 3.0 3.0 3.0 1.011
(score) (3–3) (2–3) (3–3) (0–1)
Interstial matrix 3.0 3.0 2.5 1.311
(score) (2–3) (2–3) (2–3) (1–2)
GS=glomerulosclerosis; LIS=lisinopril treated from 50 to 60 weeks of age.
Data are expressed as median (range) or mean7s.d.
*Po0.05 vs MWF rats at 50 and 60 weeks of age, 11Po0.01 vs all MWF groups,
#Po0.05 vs MWF rats at 50 weeks of age, ++Po0.01 vs MWF rats at 60 weeks of age.
a b
c d
Figure 2 | Representative microphotographs of kidney tissue in
untreated MWF rats at (a) 50 and (b) 60 weeks of age, (c) in MWF
rats treated with lisinopril from 50 to 60 weeks of age, and (d) in
control Wistar rats at 60 weeks of age. Periodic acid-Schiff staining
at original magnification 100.
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lesser degree (mean GS index 1.1, range 0.8–1.6). Although
these results suggest a tendency of reversal of GS upon
treatment, they do not provide the actual change in sclerosis
volume and, eventually, the extent of capillary tissue
regenerated, if any, by the treatment. Thus, we performed
serial section analysis in 100 randomly selected glomeruli per
each MWF group (n¼ 10–14 glomerular tuft in each animal),
with complete reconstruction of the entire capillary tuft. As
shown in Figure 3, mean volume of the glomerular tuft did
not change significantly in untreated animals between 50 and
60 weeks and was not significantly altered by lisinopril
treatment. On the contrary, the percentage of glomerular
capillary tuft occupied by sclerosis averaged 0.4370.10mm3
106 in untreated MWF 50W group, and significantly
increased to 0.7770.04 mm3 106 (Po0.01) with age
(MWF 60W), while in animals treated with lisinopril
(MWFþ LIS), sclerosis volume averaged only
0.2970.1 mm3 106, a value significantly lower than even
that calculated in MWF at the starting of the treatment
(MWF 50W, Po0.01). Our 3D morphological analysis of
individual glomeruli allowed to estimate the incidence and
extent of sclerotic change in the populations of reconstructed
glomeruli. The percentage of each capillary tuft volume
affected by sclerosis is plotted in Figure 3. At 50 weeks (MWF
50W), all but one glomerulus were affected by some degree of
sclerosis and a few were completely sclerosed. At 60 weeks of
age, in untreated rats (MWF 60W), the sclerosis was more
extensive (see Figure 3), and a higher number of glomeruli
were completely sclerosed (about 30%). Lisinopril treatment
reversed the pattern of GS. Thus, the percentage of tuft
volume affected by sclerosis was lower in treated rats than in
MWF rats at 50 weeks. In detail, 23% of the glomeruli of
treated animals at 60 weeks of age were not affected by
sclerosis at all, and the percentage of capillary tuft affected by
sclerosis was reduced by 34.9% (from 53.1 to 34.5% in MWF
50W and MWFþ LIS, respectively). On the other side,
considering the volume of the capillary tuft not affected by
sclerosis, this averaged 0.5370.03 mm3 106 in MWF rats
at 50 weeks and increased to 0.7470.05 mm3 106 in
treated animals 10 weeks later, with an average increase of
40%. Of note, on the contrary, untreated rats lost almost
70% of normal glomerular volume in the 10 week
observation period. The pattern of these changes with age
(incidence and extent of sclerosis), and the effect of treatment
is visualized in Figure 4. In the figure, two surfaces are
represented for each glomerular tuft. The gray color
surfaces represent the outer part of a glomerular capillary
tuft, while the red surfaces represent areas of GS. As shown in
the pictures, GS increased in extent in untreated animals
from 50 to 60 weeks of age, while in treated animals
(MWFþ LIS), there appears to be a regression of sclerotic
lesions (Figure 4).
Besides glomerular, tubular structure and interstitial
volume were also markedly altered in MWF rats. Interstitial
volume increased significantly in MWF rats over normal
controls already at 50 weeks and further rose at 60 weeks, as
shown in Table 1. Lisinopril prevented interstitial volume
expansion with age. In treated animals, interstitial volume
was significantly lower (Po0.01) than that in untreated
MWF rats at the same age, and comparable to untreated
MWF rats at 50 weeks. Also, tubular atrophy and interstitial
inflammation were present in MWF as compared to Wistar
animals at 50 weeks (see Table 1). Despite the lower volume
density of interstitial area, score for tubular atrophy and
interstitial inflammation failed to detect statistically signifi-
cant differences between treated and untreated animals at
60 weeks.
Morphological alterations of kidney structure in MWF
rats were associated with the abnormal expression of TGF-b
(as reported in Figure 5 and in Table 2) in glomerular tufts
already at 50 weeks, which further increased with age.
Glomerular TGF-b expression was normalized in MWF rats
by lisinopril treatment, being comparable to that of normal
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Figure 3 | (a) Average volume of individual glomeruli, sclerosed
and nonsclerosed glomerular mass, as reconstructed from
untreated (MWF 50W and MWF 60W) and lisinopril-treated rats.
Effect of aging on the percentage of glomerular capillary tuft affected
by sclerosis in 100 glomeruli reconstructed from MWF rats at 50 and
60 weeks of age (b; values for each glomerular capillary were
calculated from serial section analysis and ordered increasingly for
each group). (c) Effect of lisinopril treatment on the percentage of
tuft volume affected by sclerosis. *Po0.05 vs MWF 50W, **Po0.01 vs
MWF 50W, 11Po0.01 vs MWF 60W.
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Wistar rats. TGF-b expression in interstitial area
was comparable between MWF rats and Wistar rats at
50 weeks. With age, this TGF-b expression numerically
increased, but the difference did not reach statistical
significance. In treated animals, TGF-b expression was
comparable to that of the control group. a-SMA expression
(see Figure 5 and Table 2) localized in glomerular capillaries
and interstitial area at 50 and 60 weeks of age in MWF rats,
while positive staining was only occasionally found in the
glomeruli of control Wistar rats. Lisinopril normalized
glomerular a-SMA expression in MWF rats, whose levels
were comparable to control Wistar rats, without affecting
a-SMA expression in interstitial area. TGF-b and a-SMA
staining were completely abrogated, omitting the primary
antibody (data not shown).
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Figure 4 | Visual representation of the distribution of sclerotic
areas within the capillary tuft in MWF 50W, MWF 60W and
MWFþ LIS group. After digital reconstructions of 100 glomerular
tufts with the corresponding sclerotic areas, the population was
ordered by the percentage of sclerotic volume and six glomeruli were
represented. #Position of the glomeruli in the ordered sequence.
Glomeruli from treated animals show actual decrease in volume
affected by sclerosis, as compared to baseline observation. On the
contrary, in untreated animals at 60W, the damage extended to
almost entire glomerular mass.
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Figure 5 | Representative images of immunohistochemistry
performed (a–d) with anti-TGF-b antibody and (e–h) with anti-a-
SMA antibody in untreated MWF rats (a and e) at 50 and
(b and f) at 60 weeks of age, in MWF rats treated with lisinopril
from (c and g) 50 to 60 weeks of age, and (d and h) in control
Wistar rats. Original magnification  250.
Table 2 | Expression of TGFb and a-SMA in glomeruli and
cortical interstitium in MWF and in Wistar rats at 60 and 50
weeks of age
Age MWF 50W MWF 60W MWF+LIS Wistar
50 weeks 60 weeks 60 weeks 60 weeks
TGF-b expression
Glomeruli 1.0 3.0 0.3++, ## 0**
(score) (1–2) (2–3) (0–1) (0–0)
Interstitial area 2.0 3.0 2.0++ 2.0++
(score) (1–2) (3–3) (2–2) (2–2)
a-SMA expression
Glomeruli 1.5 2.0 0.5 0.5#, ++
(score) (1–2) (1–3) (0–1) (0-1)
Interstitial area 1.5 2.0 1.0#, + 01
(score) (1–2) (1–2) (1–1) (0-1)
Data are expressed as median (range).
**Po0.01 vs MWF rats at 50 and 60 weeks of age, 1Po0.05 vs all MWF groups,
*Po0.05 vs MWF rats at 50 weeks of age, ##Po0.01 vs MWF rats at 50 weeks of age,
+Po0.05 vs MWF rats at 60 weeks of age and ++Po0.01 vs MWF rats at 60 weeks of
age.
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DISCUSSION
The present results show that, in a model of spontaneous
renal disease leading to proteinuria, GS, and loss of kidney
function,20 ACE inhibition significantly reduced glomerular
sclerotic lesions and promoted the formation of new normal
capillary tissue. That glomerular structural changes can be
ameliorated by drugs that antagonize the biological action of
AII has been shown consistently in different experimental
models.10–14 However, previous studies did not allow to
quantify the effective reduction in the extent of sclerotic
volume and, more importantly, they could not quantify
whether some degree of glomerular capillary regeneration is
induced by the therapy. Studies aimed at establishing whether
these therapies can effectively promote the formation of
intact tissue are of paramount importance to predict if
regression of structural changes will be associated with
amelioration of renal function in the long term.
Using 3D analysis of individual capillary tufts, here we
directly quantified total capillary tuft volume and the volume
affected by sclerosis. Total capillary tuft did not change
significantly with ACE inhibition, and this is in line with
previous observation in the renal ablation model in which
ACE inhibition only numerically reduced capillary tuft
volume.14 At variance, our results show that the volume of
capillary tuft affected by sclerosis was significantly reduced by
treatment. The difference between these two mean volumes
indicates that sclerosis was effectively reabsorbed and, on the
other hand, that a consistent amount of glomerular tissue
regained normal structure, suggesting neoformation of
glomerular capillary segments. In detail, at baseline, sclerotic
changes affected the entire glomerular population, all but one
glomerulus showed different degrees of sclerosis (see
Figure 3). Upon lisinopril treatment, the volume extent of
these changes uniformly decreased with more relevant effects
in glomeruli affected by less than 25% in tuft volume.
Actually, an important percentage (23%) of glomeruli were
no longer affected by sclerosis after the treatment. This
observation strongly supports the hypothesis that small
sclerosis changes can be completely regressed by inhibition of
ACE. In glomeruli more heavily affected by sclerosis, a
significant reduction of the sclerosis volume was also
observed, while, as expected, glomeruli occupied by sclerosis
for more than 80% of their tuft volume did not benefit from
treatment. Considering the entire sample of the glomerular
population used for morphometrical analysis, the total
sclerotic volume was reduced by 34.9%. This result is
visualized by the images reported in Figure 4. On the other
hand, taking into consideration that mean glomerular
volume did not change significantly during treatment, our
calculations showed that the volume of normal capillary
tissue increased by 40% during this period.
The mechanisms by which AII antagonism induced
regression of sclerotic scar tissue and increased the volume
of nonsclerosed capillary tuft are behind the aims of the
present study. However, previous data reported in literature
indicate some potential mechanisms. Among them, a
decreased mRNA and protein expression of plasminogen
activator inhibitor-1 (PAI-1) by ACE inhibition in an aging
model of nephropathy in the rat and in the renal ablation
model has been reported to characterize remodeling of GS.12
This observation indicates direct involvement of matrix
protein degradation in the process of sclerosis regression.
Here, we focused on the renal expression of TGF-b and
a-SMA. We observed an age-related increase in glomerular
expression of both proteins in MWF rats, which may explain
the massive fibrosis and cell proliferation we have previously
documented in this model by morphometrical analysis.19 The
fact that ACE inhibition favorably affected TGF-b and a-SMA
expression at glomerular level may suggest that regression of
sclerotic lesions is also related to reduction in extracellular
matrix production and accumulation by glomerular cells as
well as to a favorable effect on glomerular cell differentiation.
Regarding the possible mechanisms that may induce
repair of glomerular capillaries, our present data cannot help
in identifying them. Recent data in the renal ablation model14
would suggest that ACE inhibition in this model is not
associated with proliferation of resident glomerular cells.
However, Asano and co-workers,21 recently demonstrated
that when podocytes are severely damaged, proliferating
parietal epithelial cells migrate onto the visceral site,
mimicking proliferating podocytes. Specific studies on
glomerular cells and related changes in glomerular capillary
architecture are needed to gain more information on this
issue. However, among possible candidates that may play a
role in this form of tissue repair, there are progenitor cells of
the bone marrow, which have been shown to interact with
glomerular cells.22,23
In conclusion, this study demonstrates that late-stage
intervention with ACE inhibitors affords consistent regres-
sion of glomerular injury and regeneration of nonsclerosed
tissue in a genetic model of renal disease. Besides indicating
the possibility to induce the regression of glomerular damage,
our results may have important implications for the
treatment of progressive chronic glomerulopathies. If these
results can be successfully transferred to the clinical
condition, they may allow to effectively reduce the use and
the costs of life-long renal replacement therapies. On the
basis of these evidences, it is of crucial importance to
investigate cellular and molecular mechanisms that underlay
this process, with the aim to extend, in incidence and
duration, the beneficial effects of these treatments.
MATERIALS AND METHODS
Study design
Twenty-five male MWF rats and four Wistar rats (Charles River
Italia S.p.A., Calco, Italy) were used. MWF rats belonging to our
colony20 were established to have a high number of surface
glomeruli, previously used for micropuncture studies.24 Animals
were divided into four groups. The first group, consisting of MWF
rats (n¼ 9), was followed until the age of 50 weeks (MWF 50W)
without treatment and was used at this age to evaluate serum
creatinine, protein excretion and to perform morphological and
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morphometrical analysis of kidney tissue. The second group of
MWF rats (n¼ 7) was followed until the age of 60 weeks (MWF
60W), and was similarly left untreated until this age, then used for
renal functional and structural evaluation. MWF rats of the third
group (n¼ 9) were left untreated until the age of 50 weeks and then
treated with a high dose of the ACE inhibitor lisinopril in drinking
water (80 mg/l) for 10 weeks (MWFþ LIS). After treatment (i.e. at
the age of 60 weeks), animals were used for kidney function and
structural evaluation. A group of Wistar rats left untreated up to 60
weeks of age was used as the control group. Serum creatinine and
protein excretion were periodically measured during the observation
period using conventional methods. All animals were maintained in
a temperature-controlled room, regulated with a 12-h light/dark
cycle, and allowed free access to water and food (standard rat chow
with 20% in protein). Animal care and treatment were conducted in
conformity with the institutional guidelines that are in compliance
with national and international laws and policies (EEC CD 86/609,
OJL 358, 1987; DL n 116, GU, 18/2/1992, Circ. N. 8, GU, 14/7/1994;
Guide for the Care and Use of Laboratory Animals, US NRC, 1996).
Morphological evaluations
Kidney tissue was obtained and processed for morphological
evaluation as described in detail previously.10 Briefly, after
anesthesia, animals were opened through a mid-line incision, and
the abdominal aorta was cannulated below the renal arteries, with a
catheter connected to a pressure transducer (Battaglia Rangoni,
Bologna, Italy). The left kidney was perfused with saline solution at
the measured arterial pressure for 5 min, and then with a solution of
1.25% glutaraldehyde in 0.1 mol/l cacodylate buffer. The kidney was
then removed, weighted and postfixed in Dubosq–Brazil fluid. After
paraffin embedding, sections 3 mm in thickness (Ultrotome V, LKB,
Bromma, Sweden) were stained with Masson’s trichrome, hematox-
ylin and eosin, and by the periodic acid-Schiff techniques, as
described previously.10
The incidence and extent of glomerular and tubular structural
lesions were estimated at light microscopy, with conventional single
section evaluation and at single glomerular capillary level. For
conventional evaluation, at least 100 glomeruli were examined for
each animal, including the superficial and juxtamedullary cortical
area. Each glomerulus was scored according to the extent of sclerotic
changes consisting of matrix deposition, capillary occlusion and
capillary tuft adhesion to Bowman’s capsule.10 Score was assigned to
0 in the absence of sclerosis, to 1 for changes affecting less than 25%
of the glomerular area, to 2 and 3 for lesions affecting 25–50 and
50–75% of the tuft, respectively, and to 4 for lesion exceeding 75% of
the tuft. The average GS index in each animal was then calculated as
weighted mean. For single glomerular volume estimation, serial
section analysis with digital image processing and 3D reconstruction
was used, with some modifications of previously described
methods.15 Briefly, for each animal, a series of serial sections of
kidney cortical tissue (3mm in thickness) was obtained and the
middle section of the series was labeled as ‘starting section’. In the
starting section, 15–20 glomeruli were randomly identified (irre-
spective of their size and the presence or extent of sclerosis), and
used for acquisition of digital images at light microscopy of the
entire glomerular capillary tuft, above and below the starting
section, until the glomerular tuft disappeared in the following
section. Digital images were processed with interactive tools (Image
J, http://rsb.info.nih.gov/ij) to outline separately the outer polygon
of the capillary tuft and, if present, the sclerotic region of the
glomerular tuft. The coordinates of each pixel of these outlines were
stored in the computer memory, and used to calculate and
graphically represent the capillary tuft area and the sclerosis area
in each section. For calculation of capillary tuft and sclerosis
volume, the sum of the respective surface areas along the entire
series of images acquired for each individual glomerulus was
performed, and multiplied by section thickness. In total, 100
glomeruli were analyzed for each MWF rat group (MWF 50W,
MWF 60W and MWFþ LIS). For visualization of the fraction of the
capillary tuft volume occupied by sclerosis at single glomerular level,
we developed a computer program in Cþ þ using the VTK
libraries (Visualization Tool Kit, http://public.kitware.com/). This
program allowed us to automatically generate 3D views of a
hypothetical surface, wrapping the glomerular capillary tufts as a
transparent gray surface, and the volume occupied by sclerotic
changes as solid red surfaces.
We also determined volume density of the cortical interstium by
digital morphometrical analysis. Briefly, in a single kidney section
for each animal, 30 systematically selected fields in the renal cortex
were digitized, and a 10 10 line orthogonal grid was digitally
overlayed (using the digital image-processing program Image J,
http://rsb.info.nih.gov/ij/). Volume density was calculated as the
ratio between grid points hitting interstitial space and total number
of grid points contained in the renal cortex. Image acquisition and
point counting were repeated until the expected probable error of
the mean volume density was less than 5%.25 Tubular structural
changes were evaluated by semiquantitative scores. Tubular atrophy,
interstitial matrix accumulation and inflammation were graded
from 0 to 3þ (0¼ no changes; 1þ ¼ changes affecting less than
25% of the sample; 2þ ¼ changes affecting 25 to 50% of the
sample; 3þ ¼ changes affecting more than 50% of the sample). At
least 10 fields per kidney slice were examined for histological scores
at low-power magnification. All tissue sections were analyzed by the
same pathologist in a single-blinded manner.
Immunohistochemical analysis
TGF-b accumulation was detected on paraffin-embedded sections
using an alkaline phosphatase-Fast Red technique.26 The slides were
heated twice for 5 min in 0.01 mol/l sodium citrate buffer, pH 6.0, in
a microwave oven at an operating frequency of 2450 MHz and
600-W power output. They were allowed to cool for 15 min and
then rinsed in distilled water twice and in phosphate-buffered saline
(PBS) for 5 min. Sections were blocked with PBS and 1% bovine
serum albumin (BSA), then incubated overnight at 41C with the
primary antibody, a polyclonal rabbit anti-TGF-b rat (1:100; Santa
Cruz Biotechnology, Santa Cruz, CA, USA). After washing in PBS,
biotinylated goat anti-rabbit IgG (1:200; Vector Laboratories,
Burlingame, CA, USA) was applied for 30 min at room temperature.
Sections were then washed with PBS and incubated with alkaline
phosphatase-conjugated streptavidin (1:50; Roche Molecular Bio-
chemicals, Mannheim, Germany) for 30 min at room temperature,
followed by washes with PBS and by development with Fast Red
substrate (Roche Molecular Biochemicals, Mannheim, Germany).
Sections were finally mounted using an aqueous mounting medium
(Bio-Optica, Milan, Italy).
The myofibroblast marker, a-SMA, was evaluated by a mouse
monoclonal antibody (1:400; Sigma Co., St Louis, MO, USA). To
serve this purpose, Dubosq–Brazil fixed and paraffin-embedded
kidney sections were deparaffinized, rehydrated and incubated for
30 min with 0.3% H2O2 in methanol to quench endogenous
peroxidase. Then the tissue was permeabilized in 0.1% Triton
X-100 in PBS 0.01 mol/l, pH 7.2, for 30 min and the sections were
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blocked with 1% PBS/BSA. Primary antibody was added overnight
at 41C, followed by the secondary antibody consisting of
biotinylated sheep anti-mouse IgG diluted 1:100, (Chemicon
Temecula, CA), avidin–biotin peroxidase complex (ABC) solution,
and finally developed with diaminobenzidine. Negative controls
were obtained by omitting the primary antibody on a second section
present on all glass slides. The staining for TGF-b and a-SMA was
assessed by a semiquantitative evaluation at light microscopy. A
score was assigned to each glomerulus observed accordingly to the
following pattern: 0, absence of staining of the glomerular tuft; 1,
weak staining; 2, staining of moderate intensity; and 3, strong
staining of the glomerular tuft. All renal tissue sections were
analyzed by the same pathologist, in a single-blinded manner.
Statistical analysis
Statistical analysis was performed using the computer software Stat
Views (Abacus Concept Inc., Berkeley, CA). Data were analyzed
using the analysis of variance with Bonferroni/Dunn test to assess
statistical significance of specific comparisons. Nonparametric data,
such as morphological scores, were analyzed with the Kruskal–Wallis
test, as specified. The level of Po0.05 was considered statistically
significant.
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